CERS
Price
$2.02
Change
-$0.06 (-2.88%)
Updated
Sep 6 closing price
54 days until earnings call
MYGN
Price
$26.97
Change
-$0.69 (-2.49%)
Updated
Sep 6 closing price
59 days until earnings call
Ad is loading...

CERS vs MYGN

Header iconCERS vs MYGN Comparison
Open Charts CERS vs MYGNBanner chart's image
Cerus
Price$2.02
Change-$0.06 (-2.88%)
Volume$694.77K
CapitalizationN/A
Myriad Genetics
Price$26.97
Change-$0.69 (-2.49%)
Volume$547.66K
CapitalizationN/A
View a ticker or compare two or three
CERS vs MYGN Comparison Chart
Loading...
CERS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MYGN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
CERS vs. MYGN commentary
Sep 08, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a Hold and MYGN is a Buy.

COMPARISON
Comparison
Sep 08, 2024
Stock price -- (CERS: $2.08 vs. MYGN: $27.64)
Brand notoriety: CERS and MYGN are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CERS: 46% vs. MYGN: 104%
Market capitalization -- CERS: $342.62M vs. MYGN: $1.93B
CERS [@Medical Specialties] is valued at $342.62M. MYGN’s [@Medical Specialties] market capitalization is $1.93B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 0 FA rating(s) are green whileMYGN’s FA Score has 1 green FA rating(s).

  • CERS’s FA Score: 0 green, 5 red.
  • MYGN’s FA Score: 1 green, 4 red.
According to our system of comparison, MYGN is a better buy in the long-term than CERS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 4 TA indicator(s) are bullish while MYGN’s TA Score has 6 bullish TA indicator(s).

  • CERS’s TA Score: 4 bullish, 4 bearish.
  • MYGN’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, MYGN is a better buy in the short-term than CERS.

Price Growth

CERS (@Medical Specialties) experienced а -9.17% price change this week, while MYGN (@Medical Specialties) price change was -2.40% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -1.45%. For the same industry, the average monthly price growth was +4.17%, and the average quarterly price growth was -7.83%.

Reported Earning Dates

CERS is expected to report earnings on Oct 31, 2024.

MYGN is expected to report earnings on Nov 05, 2024.

Industries' Descriptions

@Medical Specialties (-1.45% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MYGN($1.93B) has a higher market cap than CERS($343M). MYGN YTD gains are higher at: 44.410 vs. CERS (-3.704). CERS has higher annual earnings (EBITDA): -26.34M vs. MYGN (-197.4M). MYGN has more cash in the bank: 141M vs. CERS (65.9M). CERS has less debt than MYGN: CERS (96M) vs MYGN (152M). MYGN has higher revenues than CERS: MYGN (753M) vs CERS (156M).
CERSMYGNCERS / MYGN
Capitalization343M1.93B18%
EBITDA-26.34M-197.4M13%
Gain YTD-3.70444.410-8%
P/E RatioN/AN/A-
Revenue156M753M21%
Total Cash65.9M141M47%
Total Debt96M152M63%
FUNDAMENTALS RATINGS
CERS vs MYGN: Fundamental Ratings
CERS
MYGN
OUTLOOK RATING
1..100
5922
VALUATION
overvalued / fair valued / undervalued
1..100
55
Fair valued
94
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9795
PRICE GROWTH RATING
1..100
5345
P/E GROWTH RATING
1..100
1001
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CERS's Valuation (55) in the Medical Specialties industry is somewhat better than the same rating for MYGN (94) in the Biotechnology industry. This means that CERS’s stock grew somewhat faster than MYGN’s over the last 12 months.

CERS's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as MYGN (100) in the Biotechnology industry. This means that CERS’s stock grew similarly to MYGN’s over the last 12 months.

MYGN's SMR Rating (95) in the Biotechnology industry is in the same range as CERS (97) in the Medical Specialties industry. This means that MYGN’s stock grew similarly to CERS’s over the last 12 months.

MYGN's Price Growth Rating (45) in the Biotechnology industry is in the same range as CERS (53) in the Medical Specialties industry. This means that MYGN’s stock grew similarly to CERS’s over the last 12 months.

MYGN's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for CERS (100) in the Medical Specialties industry. This means that MYGN’s stock grew significantly faster than CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSMYGN
RSI
ODDS (%)
N/A
Bullish Trend 3 days ago
78%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
76%
Momentum
ODDS (%)
Bearish Trend 3 days ago
87%
Bearish Trend 3 days ago
86%
MACD
ODDS (%)
Bearish Trend 3 days ago
77%
Bearish Trend 5 days ago
80%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
84%
Bearish Trend 3 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
80%
Bullish Trend 3 days ago
78%
Advances
ODDS (%)
Bullish Trend 13 days ago
79%
Bullish Trend 9 days ago
78%
Declines
ODDS (%)
Bearish Trend 3 days ago
82%
Bearish Trend 4 days ago
77%
BollingerBands
ODDS (%)
Bullish Trend 5 days ago
71%
Bullish Trend 3 days ago
82%
Aroon
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
79%
View a ticker or compare two or three
Ad is loading...
CERS
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
MYGN
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
UGPSX14.950.18
+1.22%
ProFunds UltraChina Service
TIGRX15.61-0.04
-0.26%
Nuveen Core Equity R6
TVIFX77.01-0.48
-0.62%
Thornburg Small/Mid Cap Core I
DHPIX17.94-0.16
-0.88%
Diamond Hill Mid Cap I
EILVX25.92-0.27
-1.03%
Eaton Vance Large-Cap Value I

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with MASS. These tickers have moved in lockstep 52% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then MASS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
-1.42%
MASS - CERS
52%
Loosely correlated
-2.68%
FLGT - CERS
51%
Loosely correlated
+1.91%
KIDS - CERS
46%
Loosely correlated
-2.87%
VCYT - CERS
45%
Loosely correlated
+0.76%
BNGO - CERS
44%
Loosely correlated
-0.18%
More